Elan chief executive Kelly Martin: the firm faces a critical moment in its volatile history with tomorrow’s EGM.

Irish biotech group Elan has been through many critical moments in its volatile history. Tomorrow, shareholders gather for an extraordinary general me(...)

While Royalty Pharma boosted its unsolicited offer to as much as $15.50 a share this month, at least five analysts covering Dublin-based Elan see the stock falling if that bid disappears

Elan shareholders risk losing $2 billion by listening to the company’s board and rejecting Royalty Pharma’s takeover bid, according to market analysts(...)

Pharmaceutical firm Elan has urged shareholders to reject “grossly inadequate” offer from Royalty Pharma

In the latest development in Royalty Pharma’s attempt to take over Elan, the Irish pharmaceutical firm has urged shareholders to “protect the value of(...)